skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Appendix C: Panel Roster and Financial Disclosures

HCV

(Last updated: September 1, 2014; last reviewed: September 1, 2014)

Hepatitis C Virus Infection
Member Financial Disclosure
Company Relationship
Bansal, Nina Mount Sinai Hospital None N/A
Kim, Arthur
Harvard Medical School Abbvie Pharmaceuticals Advisory Board, Consultant, Research Support
Bristol-Myers Squibb Advisory Board, Consultant
Gilead Consultant, Research Support
Kim, Nina University of Washington None N/A
Naggie, Susanna Duke University Abbvie Advisory Board, Research Support
Achillion Consultant, Research Support
BMS Advisory Board, Research Support
Gilead Sciences Advisory Board, Research Support
Janssen Research Support
Merck Advisory Board, Research Support
Vertex Pharmaceuticals Research Support
Sulkowski, Mark* Johns Hopkins University AbbVie Advisory Board, Research Support
Bristol-Myers Squibb Advisory Board, Research Support
Gilead Advisory Board, Research Support
Janssen Advisory Board, Research Support
Merck Advisory Board, Research Support
Wyles, David University of California, San Diego AbbVie Consultant, Research Support
Bristol-Myers Squibb Consultant, Research Support
Gilead Consultant, Research Support
Janssen Pharmaceuticals Advisory Board
Merck Consultant, Research Support
Tacere Research Support
Vertex Research Support
* Group lead

Note: Members were asked to disclose all relationships from 24 months prior to the reviewed date. The period of reporting was from September 1, 2012, through September 1, 2014.

Back to Top